Askal Ali to Disease-Free Survival
This is a "connection" page, showing publications Askal Ali has written about Disease-Free Survival.
Connection Strength
0.171
-
Diaby V, Adunlin G, Ali AA, Tawk R. Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast Cancer Res Treat. 2014 Aug; 146(3):669-73.
Score: 0.108
-
Diaby V, Ali AA, Williams KJ, Ezendu K, Soto-Perez-de-Celis E, Chavarri-Guerra Y, de Lima Lopes G. Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. Breast Cancer Res Treat. 2017 Dec; 166(3):951-963.
Score: 0.033
-
Diaby V, Ali AA, Adunlin G, Kohn CG, Montero AJ. Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Curr Med Res Opin. 2016 06; 32(6):991-6.
Score: 0.030